One-year efficacy of tenofovir alafenamide in patients with chronic hepatitis B: An observational study

Non-inferior antiviral efficacy and better renal safety have been reported in chronic hepatitis B patients with tenofovir alafenamide (TAF) treatment. The experience in real-world clinical practice is limited.We aimed to explore the efficacy after 1-year TAF treatment.A total of 148 patients (42 HBeAg-positive and 106 HBeAg-negative) with TAF treatment ≥1 year were included. Virological suppression (<20 IU/mL or undetectable), HBsAg level, alanine aminotransferase (ALT) normalization (≤36 U/L), and estimated glomerular filtration rate (eGFR) were analyzed at 1 year. Multivariate logistic regression analysis was performed to determine the associated factors for virological suppression and ALT normalization.Virological suppression was achieved in 83% and the 1-year median decline of hepatitis B virus DNA was 5.18 log IU/mL. ALT normalization occurred in 75.7%. HBsAg level decreased at a median of 0.27 log IU/mL with significant difference from baseline (P < .001). Baseline ALT (odds ratio [OR] 1.005, 95% confidence interval [CI] 1.000–1.010, P = .036) and hepatitis B virus DNA (OR 0.222, 95% CI 0.079–0.621, P = .004) were significant factors for 1-year virological suppression. Age (OR 1.064, 95% CI 1.003–1.130, P = .041) was associated with ALT normalization. Significant changes were observed in creatinine (mean increase 0.03 mg/dL, P = .011) and eGFR (mean decrease 2.6 mL/min/1.73 m², P = .004) after 1-year TAF treatment.One-year TAF treatment came to good virological response, modest ALT normalization rate and significant HBsAg decline. The observation of significant changes in eGFR warranted further studies.     

Nanocomposites based on the graphene family for food packaging: historical perspective,preparation methods,and properties

Nanotechnology experienced a great technological advance after the discovery of the graphene family (graphene – Gr, graphene oxide – GO, and reduced graphene oxide-rGO). Based on the excellent properties of these materials, it is possible to develop novel polymeric nanocomposites for several applications in our daily routine. One of the most prominent applications is for food packaging, offering nanocomposites with improved thermal, mechanical, anti-microbial, and barrier properties against gas and water vapor. This paper reviewed food packaging from its inception to the present day, with the development of more resistant and intelligent packaging. Herein, the most common combinations of polymeric matrices (derived from non-renewable and renewable sources) with Gr, GO, and rGO and their typical preparation methods are presented. Besides, the interactions present in these nanocomposites will be discussed in detail, and their final properties will be thoroughly analyzed as a function of the preparation technique and graphene family-matrix combinations.

Food packaging based on nanotechnology of polymeric nanocomposites of graphene and graphene oxide results in packaging with better thermal, mechanical, antimicrobial, electrical packaging, moisture barrier and gas properties.     

经皮穿刺联合内镜下胃造瘘术的临床应用

目的探讨经皮穿刺内镜下胃造瘘术(percutaneous endoscopic gastrostomy,PEG)的临床应用价值。方法 2003年5月～2010年5月,因各种原因造成的经口进食困难引起营养不良需长期营养支持的患者66例,在本院内镜中心行PEG,术后给予肠内营养。结果所有患者成功完成内镜下胃造瘘术,平均耗时20min。术后跟踪随访,所有患者造瘘管置入后营养迅速恢复,停止静脉补液。造瘘管最长留置时间2年。5例患者发生造瘘管周围皮肤感染,6例出现反流性食管炎,2例发生造瘘管旁渗血,对症处理后治愈。无消化道出血、腹膜炎等严重并发症。结论 PEG是作为胃肠减压和肠内营养替代鼻饲的一种新的治疗方法 ,其技术操作简单易行、安全、有效并发症少,创伤小,值得临床推广应用。     

成人间活体扩大右半肝移植治疗急性肝功能衰竭

目的介绍成人间活体扩大右半肝移植治疗急性肝功能衰竭的临床经验。方法对1例42岁男性急性肝功能衰竭合并肝性脑病Ⅲ期患者行活体扩大右半肝移植治疗。其45岁姐姐为供者,CT评估供者包含肝中静脉的扩大右半肝体积为728．4cm^2（801g）,供肝／受者体重比为1．3％。供肝之肝右、中静脉整形后与受者整形后之肝右静脉行端-侧吻合;供受者门静脉、肝动脉行端．端吻合。供肝胆管整形后与受者胆总管行端-端吻合。结果供、受者手术均成功。供者术后恢复顺利,受者术后8h恢复意识,14d后丙氨酸转氨酶、总胆红素等指标首次下降至正常水平。术后16d曾出现转氨酶明显升高,给予甲泼尼龙1000mg冲击治疗后恢复正常。随访至今,供受者已健康生存8个月,均未出现胆管、肝动脉及静脉回流等并发症。结论扩大右半肝移植在技术上完全可行。能为成人患者提供足够重量的移植物,尤其对于急性肝功能衰竭患者具有重要意义,术前精确的影像学评估,熟练的肝切除和肝移植技术是确保该类手术成功的关键因素。     

上腹部器官簇移植手术方式的探讨

目的探讨上腹部器官簇移植治疗多脏器恶性肿瘤的可行性及临床效果。方法上腹部器官簇移植受者2例,其中男、女各1例;均为胰腺癌肝转移患者。2例患者分别于2004年5月和8月接受上腹部器官簇移植治疗,切除脏器包括全胃、肝脏、胰腺、脾脏、十二指肠及部分空肠,移植器官簇包括肝脏、胰腺、十二指肠。其中1例胰腺肿物侵犯肠系膜上动脉（SMA）,切断SMA后,其远端与右髂总动脉吻合重建血供。结果2例患者于术后4h及5h清醒,8h及10h后撤除呼吸机;术后第3天及第5天从外科加强治疗病房转至普通病房。肝功能指标在手术1周后趋于正常;胰腺功能在10d内达到正常范围。1例患者存活12个月,死于肿瘤复发;另1例术后恢复平稳,术后20d自动出院。结论肝胰十二指肠器官簇移植为上腹部局部多脏器恶性肿瘤提供了一种手术上可行并具有一定疗效的治疗方法。     

模块分叉支架型血管重建犬主动脉弓的可行性研究

目的设计制作腔内重建犬主动脉弓的模块分叉支架型血管,研究其腔内重建主动脉弓的可行性。方法全组10例动物,主动脉造影测量升主动脉、主动脉弓及其分支血管的相关数据,设计并制作适合于重建犬主动脉弓的模块分叉支架型血管;在X线透视引导下,依次自右锁骨下动脉、左锁骨下动脉及股动脉植入支架型血管的三个模块,并在体内对接,完成主动脉弓的重建;观察移植物形态结构、主动脉血流动力学变化及内漏发生状况。结果8例成功完成各模块的植入,另2例分别于术中死于冠状动脉被封堵和左锁骨下动脉破裂。成功完成介入操作的8例动物术中造影结果显示移植物位置及形态良好,冠状动脉及颈总动脉血流通畅,其中2例发现近端I型内漏。结论应用模块分叉支架型血管腔内重建犬主动脉弓在技术方案上是可行的;对腔内重建人体主动脉弓的研究具有指导意义。